Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q3 2016 · 10-Q
Revenue$12.54M$12.54M−48.1% vs Q3 2015 Net Income-$20.76M-$20.76MN/M vs Q3 2015 EPS Diluted-$0.28-$0.28N/M vs Q3 2015 Operating Income-$20,195,483N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$19,117,521N/M Margins · derivedOperating margin-161.0%−176.5 pt vs Q3 2015
Net margin-165.5%−188.7 pt vs Q3 2015
ended Sep 30, 2016 · filed Nov 9, 2016 · 40 d after period end